EverHint – SMA20 × SMA50 Crossover Signals for Jan 14, 2026 – Healthcare Leads with 7 Setups
What This Signal Is (Quick)
This strategy detects fresh crossovers between the 20-day simple moving average (SMA20) and the 50-day simple moving average (SMA50):
-
Buy Signal (SMA20_x_SMA50_Buy) - "Golden Cross": SMA(20) crosses above SMA(50) on today's close
- Short-term momentum (20 days) exceeds medium-term trend (50 days)
- Bullish trend confirmation with high reliability
- Ideal for medium-term trend following (4-12 week holding periods)
-
Sell Signal (SMA20_x_SMA50_Sell) - "Death Cross": SMA(20) crosses below SMA(50) on today's close
- Short-term momentum weakens below medium-term trend
- Bearish trend confirmation
- Can signal exit points or trend reversal alerts
Key Characteristics:
- Uses two SMAs (both simple moving averages) for maximum stability
- Most stable strategy - fewer signals but highest quality (fewer whipsaws)
- Better suited for medium-term trends with confirmed momentum
- Lower risk entries compared to faster EMA-based strategies
Key Criteria:
-
Buy: SMA20 crosses above SMA50
-
Sell: SMA20 crosses below SMA50
-
Minimum ADV: $40M (liquidity filter)
-
Earnings buffer: 7 days pre/post earnings
-
Fresh crossover: Detected on today's close
Holding Period: 2-6 weeks
Risk Level: Medium
How We Ranked Today
Ranked by RSI (lower RSI = more oversold for buy signals)
📊 SMA20 × SMA50 Crossover Signals (Top 15 of 35 total)
Ranked by rsi14:
| Rank | Ticker | Company | Sector | Last ($) | RSI14 | Insider Net | Days → Earnings | Est EPS | Mkt Cap ($B) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INTU | Intuit Inc. | Technology | 566.60 | 16.2 | $-6.4M | 41 | $35.71 | 157.7 |
| 2 | ATEC | Alphatec Holdings, Inc. | Healthcare | 15.95 | 23.9 | $-43.0M | 42 | $1.72 | 2.4 |
| 3 | PGR | Progressive Corporatio... | Financial Services | 205.50 | 25.3 | $-603K | 21 | $16.18 | 120.5 |
| 4 | THG | Hanover Insurance Grou... | Financial Services | 170.66 | 25.7 | — | 20 | $17.60 | 6.1 |
| 5 | OCUL | Ocular Therapeutix, Inc. | Healthcare | 11.07 | 25.8 | — | 47 | $0.30 | 2.4 |
| 6 | ZWS | Zurn Elkay Water Solut... | Industrials | 46.55 | 32.9 | $-960K | 20 | $2.27 | 7.8 |
| 7 | UWMC | UWM Holdings Corporation | Financial Services | 5.45 | 37.2 | $-59.6M | 42 | $0.77 | 8.3 |
| 8 | ESS | Essex Property Trust, ... | Real Estate | 253.18 | 41.9 | — | 20 | $0.00 | 16.3 |
| 9 | ABBV | AbbVie Inc. | Healthcare | 221.89 | 42.0 | — | 16 | $18.94 | 392.1 |
| 10 | NFG | National Fuel Gas Company | Energy | 80.56 | 42.2 | — | 21 | $8.40 | 7.3 |
| 11 | CVLT | Commvault Systems, Inc. | Technology | 124.38 | 43.8 | — | 13 | $5.34 | 5.5 |
| 12 | SMMT | Summit Therapeutics Inc. | Healthcare | 17.65 | 46.9 | $+11.0M | 40 | $1.26 | 13.1 |
| 13 | VNOM | Viper Energy, Inc. | Energy | 37.93 | 47.1 | — | 40 | $0.00 | 12.4 |
| 14 | TLN | Talen Energy Corporation | Utilities | 374.83 | 47.1 | — | 43 | $36.80 | 17.1 |
| 15 | PCVX | Vaxcyte, Inc. | Healthcare | 48.51 | 53.3 | $-322K | 41 | $2.23 | 6.4 |
Field Notes
Sector concentration: Healthcare (7), Technology (7), Basic Materials (3)
Insider selling: ELVN (Enliven Therapeutics, Inc., $-3.5M), INTU (Intuit Inc., $-6.4M), UWMC (UWM Holdings Corporation, $-59.6M)
Insider buying: PRMB (Primo Brands Corporation, $+3.2M), LYB (LyondellBasell Industries NV, $+247K), SMMT (Summit Therapeutics Inc., $+11.0M)
Data coverage: 42.9% insider, 100.0% earnings, 100.0% analyst, 31.4% news
Recent Headlines
ABBV (AbbVie Inc.)
- AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript (source)
- AbbVie plans to build out its presence in obesity market (source)
- Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? (source)
- First Look: Alphabet $4T, Nvidia China OK, Boeing Tops Airbus (source)
- ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon (source)
- Why AbbVie (ABBV) is a Top Value Stock for the Long-Term (source)
- Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (source)
- Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings? (source)
- AbbVie Secures Tariff Relief Pact (source)
- AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines (source)
- First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals (source)
- Breakfast News: Trading Revenue Lifts JPMorgan (source)
- AbbVie reaches 3-year deal with White House to lower drug prices (source)
- AbbVie Strikes a $100 Billion Deal With Trump. How the Drugmaker Will Dodge Tariffs. (source)
- AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices (source)
- Abbvie, US reach agreement to cut drug prices (source)
- AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans (source)
- AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors (source)
- AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States (source)
- West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie (source)
- 2 Healthcare Stocks That Can Diversify a Tech-Heavy Portfolio (source)
- Merck Eyes Revolution Medicines in a Potential $32 Billion Deal (source)
- Here's What We Expect From AbbVie's Immunology Segment in Q4 (source)
- First Look: GM's $7.1B EV Charge, Paramount's $30 WBD Bid (source)
- Clear Harbor Asset Management LLC Decreases Stake in AbbVie Inc. $ABBV (source)
- Ferguson Wellman Capital Management Inc. Purchases 3,260 Shares of AbbVie Inc. $ABBV (source)
- AbbVie Inc. $ABBV Shares Bought by Duncker Streett & Co. Inc. (source)
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight (source)
- AbbVie: The Dividend Does Not Lie (source)
- AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling. (source)
- Breakfast News: Defense Stocks Whipsaw (source)
- AbbVie Inc. $ABBV Stock Holdings Increased by CX Institutional (source)
- Why Revolution Medicines Shares Are Sliding After Hours On Wednesday (source)
- AbbVie in talks to buy biotech Revolution Medicines, WSJ reports (source)
- AbbVie Near Deal for Revolution Medicines (source)
- Why Investors Need to Take Advantage of These 2 Medical Stocks Now (source)
- AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call (source)
- AbbVie Inc. $ABBV Shares Acquired by Cerity Partners LLC (source)
ATEC (Alphatec Holdings, Inc.)
- EVP People and Culture Sells ATEC 33K Shares for $679K (source)
- Alphatec Holdings, Inc. (ATEC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript (source)
- ATEC and Theradaptive Enter Strategic Partnership for Breakthrough Regenerative Technology in Spinal Fusion (source)
- ATEC Announces Select Preliminary Financial Results for 2025 and Provides 2026 Outlook (source)
- Alphatec Stock Up 126% as CEO Sells $2 Million in Shares -- Here's What Investors Should Know (source)
INTU (Intuit Inc.)
- Intuit Inc. (INTU) is Attracting Investor Attention: Here is What You Should Know (source)
- Here's Why Intuit (INTU) is a Strong Growth Stock (source)
SMMT (Summit Therapeutics Inc.)
- Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (source)
UWMC (UWM Holdings Corporation)
- Market Today: Banks, Big Tech, Biopharma and Energy Move on Policy and Deals (source)
- UWMC CEO Goes On Selling Spree Of Millions of Insider Shares (source)
VNOM (Viper Energy, Inc.)
- Trilogy Capital Inc. Buys 39,315 Shares of Viper Energy Inc. $VNOM (source)
- Viper Energy, Inc., a Subsidiary of Diamondback Energy, Inc., Schedules Fourth Quarter 2025 Conference Call for February 24, 2026 (source)
Market Context
The broader market exhibited mixed performance on January 14, 2026, with the S&P 500 down 0.16% and the Nasdaq declining 0.39%, while the Dow Jones edged higher by 0.13%. This divergence suggests a subtle rotation away from growth-oriented areas toward more stable segments, aligning with the top-performing Healthcare sector amid 35 SMA20/SMA50 signals. SMA crossover strategies like this thrive in trending environments, but the slight downward bias in major indices tempers overall bullish conviction, potentially filtering signals toward sectors showing relative strength.
VIX rose 1.59% to 16.59, signaling moderately elevated volatility that could amplify intraday swings and increase the risk of false crossovers in SMA20/SMA50 setups. While not at fear-driven levels, this uptick curbs aggressive risk appetite, as evidenced by Nasdaq's underperformance, making it prudent to prioritize signals with confirmed momentum above the SMA50 to avoid whipsaws in choppy conditions.
Sector rotation implications favor defensive plays like Healthcare, where signals may hold more reliability amid broader market hesitation. With risk appetite subdued, traders should focus on SMA20/SMA50 bullish crossovers in leading sectors for higher-probability entries, while monitoring VIX for any further creep that could disrupt short-term trends.
Vlad's Take (EverHint)
Today's signals: Strong sector concentration in Healthcare (7 signals) suggests sector-specific rotation. 3 signals with insider buying adds conviction. 12 signals showing insider selling warrant caution.
Sharing Call-to-Action
🔍 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/